Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)

Clinical trial NCT07326592 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07326592
Sponsor: CSL Behring
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Alpha1 Antitrypsin Deficiency Alpha1-Proteinase Inhibitor Deficiency Emphysema

Start date: 2026-07-20
Primary completion: 2033-09-15
Enrollment: 270

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.